Diamyd Medical

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development.

Diamyd Medical develops the diabetes vaccine Diamyd, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.